期刊
PHARMACEUTICALS
卷 3, 期 4, 页码 1122-1138出版社
MDPI
DOI: 10.3390/ph3041122
关键词
tamoxifen; CYP2D6 genotyping; breast cancer
资金
- European Society of Medical Oncology (ESMO), Viganello-Lugano Switzerland
- CRUK, Breast Cancer Campaign
- NIHR Manchester Biomedical Research Centre
Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据